Is rsv vaccination worth it

The short version: RSV shots can cut hospitalizations in some groups, but the safety data is thinner than the marketing, and for healthy people the benefit is small.

The honest answer depends entirely on who you are. For infants, the evidence is real. A randomized trial of the new antibody shot clesrovimab in about 3,600 infants found it cut RSV hospitalizations by roughly 91% in the first season, though it only prevented about 60% of medically attended lung infections [1]. The older antibody nirsevimab showed similar numbers, around 83% against hospitalization in a large pragmatic trial [5]. Those are hard clinical endpoints, not antibody counts. For older adults, the vaccine trials show about 66-83% protection against RSV lung disease and over 90% against severe infection, but those numbers come from manufacturer-funded trials and a narrative review, not independent replication [4]. For pregnant women, the picture gets murkier. The Abrysvo trial showed real protection for infants, about 69% against severe disease in the first six months [8]. But the same trial found more preterm births in the vaccinated group, 5.7% versus 4.7%, and more pregnancy-related serious complications, 4.1% versus 3.3% [8]. The FDA itself said the data could not rule out a causal link [8]. A separate GSK maternal vaccine trial was stopped early because of even worse preterm birth numbers, 6.8% versus 4.9%, and a numerical imbalance in infant deaths [6]. A real-world VAERS analysis also flagged preterm birth as a disproportionate reporting signal after maternal RSV vaccination [7].

Here is the uncomfortable part the brochures skip. The trials that show benefit mostly compare vaccinated people to placebo, which is good. But the long-term safety data barely exists. These products have been on the market for a few seasons. Nobody has published a multi-year follow-up on immune imprinting, on whether blocking one season of RSV shifts the age of first infection to a worse time, or on what repeated dosing does to the immune repertoire. The resistance data is already appearing, with reduced susceptibility in some RSV-B breakthrough infections after nirsevimab [5]. And the economics are telling. The cost-effectiveness analysis for clesrovimab came in at about $105,000 per quality-adjusted life year, which is right at the edge of what systems consider worth paying [1]. That is not a safety signal, but it is a reminder that these are products with a price tag, not public health necessities.

For a healthy term infant, the antibody shot is a reasonable choice if you want to avoid a hospital stay, and the trial evidence supports it. For a pregnant woman, the benefit to the baby is real but the preterm birth signal is not nothing, and the FDA could not clear it. For a healthy older adult, the benefit is modest and the evidence is entirely from the companies that sell the product. Nobody has run the study that would settle the long-term questions, comparing vaccinated to unvaccinated people over years and watching all-cause outcomes, not just RSV. That study is absent because nobody profits from it.

My call: worth it for infants in their first RSV season, especially premature ones, based on hard hospitalization data. Not clearly worth it for pregnant women given the preterm birth signal. Marginal for healthy older adults, and the evidence base is too conflicted to call it a clear win. Confidence: moderate for infants, low for pregnant women and older adults.